Brian Hess

ORCID: 0000-0003-0176-2050

Also affiliated with MUSC Hollings Cancer Center

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma”.

Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma

New England Journal of Medicine(2024)10.1056/nejmoa2405888

N/A

3.4DataRank · unranked

211 citations

Michael LeBlanc, Sharon M. Castellino, Hongli Li, Sarah C. Rutherford, Andrew M. Evens +42 more

Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4575

N/A

1.7DataRank · unranked

56 citations

Brian Hess, Veronika Bachanová, Nancy L. Bartlett, Melissa M. Berrien-Elliott, Ethan McClain +21 more

NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826

Hematological Oncology(2023)10.1002/hon.3163_5

N/A

0.464DataRank · unranked

21 citations

Michael LeBlanc, Sharon M. Castellino, Huilin Li, Sarah C. Rutherford, Andrew M. Evens +41 more

A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma

Blood Advances(2023)10.1182/bloodadvances.2022008916

N/A

0DataRank · unranked

29 citations

Subir Goyal, Jeffrey M. Switchenko, Jason T. Romancik, Manali Kamdar, Irl Brian Greenwell +17 more